Control Bionics Valuation

Is CBL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CBL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CBL's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CBL's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CBL?

Key metric: As CBL is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for CBL. This is calculated by dividing CBL's market cap by their current revenue.
What is CBL's PS Ratio?
PS Ratio	2.8x
Sales	AU$5.35m
Market Cap	AU$14.85m

CBL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	2.8x
Enterprise Value/EBITDA	-2.9x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does CBL's PS Ratio compare to its peers?

The above table shows the PS ratio for CBL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	8.8x
LBT Clever Culture Systems	25.2x	n/a	AU$31.6m
UCM Uscom	2.2x	n/a	AU$8.0m
RHT Resonance Health	3.1x	n/a	AU$26.7m
UBI Universal Biosensors	4.8x	n/a	AU$34.3m
CBL Control Bionics	2.8x	n/a	AU$14.9m

Price-To-Sales vs Peers: CBL is good value based on its Price-To-Sales Ratio (2.8x) compared to the peer average (8.8x).

Price to Sales Ratio vs Industry

How does CBL's PS Ratio compare vs other companies in the AU Medical Equipment Industry?

9 Companies	Price / Sales	Estimated Growth	Market Cap
SDI SDI	1.1x	5.4%	US$81.57m
SOM SomnoMed	0.7x	9.0%	US$39.36m
CMP Compumedics	1x	n/a	US$32.28m
NXS Next Science	1.1x	30.6%	US$25.66m

9 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: CBL is good value based on its Price-To-Sales Ratio (2.8x) compared to the Australian Medical Equipment industry average (4.1x).

Price to Sales Ratio vs Fair Ratio

What is CBL's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CBL PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	2.8x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate CBL's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

SDI

AU$122.4m

Engages in the research and development, manufacture, and marketing of dental restorative materials, whitening systems, and other dental materials in Australia, Europe, the United States, and Brazil.

SDI

AU$1.03

-4.2%

30.4%

CardieX

AU$30.9m

Engages in the design, manufacture, and marketing of medical devices used in cardiovascular health management in the Americas, Europe, and the Asia Pacific.

CDX

AU$0.10

-22.2%

n/a

Nova Eye Medical

AU$34.4m

Designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally.

EYE

AU$0.15

1.7%

17.3%